Downregulation of T-bet/GATA-3 ratio induced by IL-11 treatment is responsible for Th1/Th2 balance restoration in human immune thrombocytopenic purpura (ITP)

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 2, 2014, Pages 183-189

  Yao, Rongxin ^a   Lin, Ying ^a   Li, Qianqian ^a   Zhou, Xieming ^a   Pan, Xiahui ^a   Bao, Yunhua ^b   He, Muqing ^a   Zhu, Baoling ^a   Guo, Wenjian ^a   Lin, Xiaoji ^a   Jin, Limin ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GATA 3; IL 11; ITP; T bet; Th1; Th2

Indexed keywords

INTERLEUKIN 11; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; GATA3 PROTEIN, HUMAN; IL11 PROTEIN, HUMAN; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CELL LINEAGE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TH1 CELL; TH2 CELL; UPREGULATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-11; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; T-BOX DOMAIN PROTEINS; TH1 CELLS; TH2 CELLS;

EID: 84904728616     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-1036-3     Document Type: Article

References (36)

1. McMillan R (2007) The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol 44(4 Suppl 5):S3-S11
2. Cines DB, Bussel JB, Liebman HA et al (2009) The ITP syndrome: pathogenic and clinical diversity. Blood 113(26):6511-6521
3. Johnsen J (2011) Pathogenesis in immune thrombocytopenia: new insights. Hematol Am Soc Hematol Educ Program 2012:306-312
4. Olsson B, Andersson PO, Jernas M et al (2003) T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9(9):1123-1124 (Pubitemid 37173694)
5. Zhang F, Chu X, Wang L et al (2006) Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 76(5):427-431
6. Zhang J, Ma D, Zhu X et al (2009) Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica 94(9):1326-1329
7. Sakakura M, Wada H, Tawara I et al (2007) Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 120(2):187-193 (Pubitemid 46754414)
8. Yu J, Heck S, Patel V et al (2008) Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 112(4):1325-1328
9. Hu Y, Ma DX, Shan NN et al (2011) Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia. PLoS One 6(10):e26522
10. Hu Y, Li H, Zhang L et al (2012) Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia. Hum Immunol 73(6):629-635
11. Wang T, Zhao H, Ren H et al (2005) Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 90(7):914-923 (Pubitemid 41020294)
12. Panitsas FP, Theodoropoulou M, Kouraklis A et al (2004) Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 103(7):2645-2647 (Pubitemid 38393019)
13. Guo C, Chu X, Shi Y et al (2007) Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 27(6):557-562
14. Shan NN, Ji XB, Wang X et al (2011) In vitro recovery of Th1/Th2 balance in PBMCs from patients with immune thrombocytopenia through the actions of IL-18BPa/Fc. Thromb Res 128(6):e119-e124
15. Shier P, Hofstra CL, Ma XJ et al (2000) Tbt-1, a new T-box transcription factor induced in activated Th1 and CD8+ T cells. Immunogenetics 51(10):771-778 (Pubitemid 30612040)
16. Szabo SJ, Kim ST, Costa GL et al (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100(6):655-669
17. Zhang DH, Cohn L, Cohn L, Ray PB et al (1997) Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem 272(34):21597-21603 (Pubitemid 27374036)
18. Ouyang W, Ranganath SH, Weindel K et al (1998) Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 9(5):745-755 (Pubitemid 28557602)
19. Farrar JD, Ouyang W, Lohning M, Assenmacher M, Radbruch A, Kanagawa O et al (2001) An instructive component in T helper cell type 2 (Th2) development mediated by GATA-3. J Exp Med 193(5):643-650
20. Chakir H, Wang H, Lefebvre DE et al (2003) T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods 278(1-2):157-169 (Pubitemid 37281199)
21. Paul SR, Bennett F, Calvetti JA et al (1990) Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 87(19):7512-7516 (Pubitemid 20341746)
22. Vadhan-Raj S (2009) Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol 46(1 Suppl 2):S26-S32
23. Schwertschlag US, Trepicchio WL, Dykstra KH et al (1999) Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 13(9):1307-1315 (Pubitemid 29429755)
24. Trepicchio WL, Ozawa M, Walters IB et al (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104(11):1527-1537 (Pubitemid 30002364)
25. Moreland L, Gugliotti R, King K et al (2001) Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res 3(4):247-252 (Pubitemid 32621964)
26. Gurfein BT, Zhang Y, Lopez CB et al (2009) IL-11 regulates autoimmune demyelination. J Immunol 183(7):4229-4240
27. Qin L, Yuan Z, Du XJ, Ma XH (2008) Curative effect of rhIL-11 on 26 patients with chromic idiopathic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(5):1219-1221
28. Zhang XL, Cheng XZ, Ye X, Shi XJ (2010) Therapeutic effect of interleukin-11 on thrombocytopenia in patients with hematologic malignancies after chemotherapy. Zhonghua Zhong Liu Za Zhi 32(9):713-715
29. Ragni MV, Jankowitz RC, Jaworski K et al (2011) Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. Thromb Haemost 106(4):641-645
30. Feinglass S, Deodhar A (2001) Treatment of lupus-induced thrombocytopenia with recombinant human interleukin-11. Arthritis Rheum 44(1):170-175 (Pubitemid 32113131)
31. Fontana V, Dudkiewicz P, Jy W et al (2008) Interleukin-11 for treatment of hepatitis C-associated ITP. Acta Haematol 119(2):126-132 (Pubitemid 351591416)
32. Bussel JB, Mukherjee R, Stone AJ (2001) A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol 66(3):172-177 (Pubitemid 32167454)
33. Curti A, Ratta M, Corinti S et al (2001) Interleukin-11 induces Th2 polarization of human CD4(+) T cells. Blood 97(9):2758-2763
34. Hill GR, Cooke KR, Teshima T et al (1998) Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest. 102(1):115-123 (Pubitemid 28323837)
35. Lazarevic V, Glimcher LH (2011) T-bet in disease. Nat Immunol 12(7):597-606
36. Ji N, Sosa RA, Forsthuber TG (2011) More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases. Immunotherapy 3(3):435-441